THE LONDON GAZETTE, 25TH NOVEMBER 1994

Product Licence Number	Company Name	Product Name	Active Ingredients	Indications	Date of Authorisation
				treatment of trachoma. However, the infectious agent is not eliminated on all occasions, as tested by immunofluorescence techniques. Miscellaneous: Trigonitis and prostatitis caused by proteus species, paittacosis, certain other infections caused by succeptible strains of bacteroides species, listeria species, rickettain species, listeria species, rickettain species (in combination with streptomycin) and bordetella pertussia, calymmato-bacterium granulomatia, spirochaetes (treponema species), bacillus anthracis, neisseria meningitis and clostridium welchii. Doxyclycline may be useful adjunct to amoebicides in the treatment of acute intestinal amoebiasis. POM	
12365/0004	Laboratoires Ethypharm	Ethypharm Doxycycline Capsules 100 mg	Doxycycline Hyclate EP 115-40 mg (equivalent to Doxycycline base 100-00 mg)	See PL/12365/0003.	11th August 1994
12365/0005	Laboratoires Ethypharm	Ethypharm Doxycycline Capsules 200 mg	Doxycycline Hyclate EP 230-80 mg (equivalent to Doxycycline base 200 00 mg)	See PL/12365/0003.	11th August 1994
12557/0028	BCM Limited	Athlete's Foot Cream	Irgasan DP 300 HSE 0-10% w/w 2,4-Dichlorobenzyl Alcohol HSE 0-50% w/w	For the treatment and prevention of Athlete's Foot. GSL	25th October 1994
12724/0041	GM Laboratories Limited	Metronidszole Tablets BP 200 mg	Metronidazole BP 204-00 mg	The treatment of septicaemia, bacterawamia, brain abaceas, osteomyellits, puerperal sepsis, pelvic abaceas and pelvic cellulitis. The prevention of post-operative infections due to anaerobic bacteria. Urogenital trichomoniasis in the female and in the male. Non-specific vaginitis. All forms of amoebiasis such as soute amoebic dysentery and amoebic liver abaceas and to eradicate cysts from asymptomatic cyst passers. Giardiasis. Acute ulcerative gingivitis. POM	1st November 1994
12724/0042	GM Laboratories Limited	Metronidazole Tablets BP 500 mg	Metronidazole BP 400.00 mg	See PL/12724/0041.	1st November 1994
12724/0043	GM Laboratories Limited	Quinine Sulphate Tablets BP 200mg	Quinine Sulphate BP 200.00mg	Treatment of plasmodium malaris infection resistant to other antimalarials, and prophylaxis in areas where P. Falciparum is resistant to chloroquine. POM	1st November 1994
12724/0044	GM Laboratories Limited	Quinine Sulphate Tablets BP 300mg	Quinine Sulphate BP 300.00mg	See PL12724/0043	1st November 1994
12724/0046	GM Laboratories Limited	Quinidine Sulphate Tablets BP 200mg	Quinidine Sulphate BP 200,00mg	Prevention and treatment of cardiac arrhythmias, including paroxysmal atrial fibrillation and flutter, paroxysmal array and ventricular tachycardia. As a maintenance therapy in cases where cardiac conversion has bejen performed, and for the prevention of extrasystoles. POM	1994
12724/0047	GM Laboratories Limited	Propranolol Tablets BP 10mg	Propranolol Hydrochloride BP 10.00mg	The Control of Hypertension. The management of Angina Pectoris. The Long Term Prophylaxis after recovery from acute myocardial infarction. The control of most forms of Cardiac Dysrhythmias. The Prophylaxis of Migraine. The Management of Essential Tremor. The relief of situational anxiety and generalised anxiety supptoms, particularly those of somatic type. Prophylaxis of upper gastro-intensitial bleeding in patients with portal hypertension and oesophageal varices. The adjunctive management of thyrotoxicosis and thyrotoxic crisis. Management of hypertrophic obstructive cardiomyopathy. Management of Phaeochromocytoms perioperatively (with an Alpha Blocker).	1st November 1994
12724/0048	GM Laboratories Limited	Propranolol Tablets BP 40mg	Propranolol Hydrochloride BP 40.00mg	See PL 12724/0047	1st November 1994
12724/0049	GM Laboratories Limited	Propranolol Tablets BP 80mg	Propranolol Hydrochloride BP 80.00mg	See PL 12724/0047	1st November 1994
12724/0050	GM Laboratories Limited	Propranoloi Tablets BP 160mg	Propranolol Hyudrochloride BP 160.00mg	See PL 12724/0047	lst November 1994